Kruidnagelolie 0,5% voor de behandeling van trigeminale neuropathie, een multicenter double-blind vehicle-controlled cross-over studie

Gilles Bossuyt

Mogelijke nieuwe behandeling voor ernstige aangezichtspijn

Een student aan de universiteit van Kortrijk heeft onlangs een interessant studievoorstel gepresenteerd. Gilles Bossuyt (21 j.) deed een literatuurstudie en concludeerde dat de olie van kruidnagels wel eens een goede therapie zou kunnen zijn voor patiënten die lijden aan trigeminale neuropathie. Deze aandoening wordt gekenmerkt door levenslange ernstige aangezichtspijn. De huidige behandelingen werken onvoldoende of hebben veel nevenwerkingen, dus een alternatieve behandeling is zeker welkom. Bij knaagdieren alsook met humane celexperimenten bewezen wetenschappers wereldwijd al de werking van kruidnagelolie. Met de studie wil de student aantonen dat de kruidnagelolie werkzaam kan zijn voor  patiënten. Wij zijn alvast benieuwd naar de resultaten!


Essential Oils Company - Clove Oil. Available at:…. (Accessed: 26th April 2019)
2. Clove. New World Encyclopedia (2008).
3. Kamatou, G. P. et al. Eugenol—From the Remote Maluku Islands to the International Market Place: A Review of a Remarkable and Versatile Molecule. Molecules 17, 6953–6981 (2012).
4. Jaganathan, S. K. & Supriyanto, E. Antiproliferative and molecular mechanism of eugenol-induced apoptosis in cancer cells. Molecules 17, 6290–304 (2012).
5. Saeed, A. S. & Gilani, H. A. Antithrombotic Activity of Clove Oil. JPMA - J. Pakistan Med. Assoc. 44, (1994).
6. Park, C. K. et al. Molecular mechanism for local anesthetic action of eugenol in the rat trigeminal system. Pain 144, 84–94 (2009).
7. PubChem - Eugenol. Available at: (Accessed: 2nd April 2019)
8. Guénette, S. A., Ross, A., Marier, J.-F., Beaudry, F. & Vachon, P. Pharmacokinetics of eugenol and its effects on thermal hypersensitivity in rats. Eur. J. Pharmacol. 562, 60–67 (2007).
9. Yang, B. H. et al. Activation of Vanilloid Receptor 1 (VR1) by Eugenol. J. Dent. Res. 82, 781–785 (2003).
10. Chung, G. et al. Activation of transient receptor potential ankyrin 1 by eugenol. Neuroscience 261, 153–160 (2014).
11. Li, H. Y., Lee, B. K., Kim, J. S., Jung, S. J. & Oh, S. B. Eugenol Inhibits ATP-induced P2X Currents in Trigeminal Ganglion Neurons. Korean J. Physiol. Pharmacol. 12, 315 (2008).
12. Park, C.-K. et al. Eugenol Inhibits Sodium Currents in Dental Afferent Neurons. J. Dent. Res. 85, 900–904 (2006).
13. Yeon, K.-Y. et al. Eugenol reverses mechanical allodynia after peripheral nerve injury by inhibiting hyperpolarization-activated cyclic nucleotide-gated (HCN) channels. Pain 152, 2108–2116 (2011).
14. Khalilzadeh, E., Hazrati, R. & Saiah, G. V. Effects of topical and systemic administration of Eugenia caryophyllata buds essential oil on corneal anesthesia and analgesia. Res. Pharm. Sci. 11, 293–302 (2016).

15. Docherty, R. J., Ginsberg, L., Jadoon, S., Orrell, R. W. & Bhattacharjee, A. TRPA1 insensitivity of human sural nerve axons after exposure to lidocaine. Pain 154, 1569–1577 (2013).
16. Leffler, A. et al. The vanilloid receptor TRPV1 is activated and sensitized by local anesthetics in rodent sensory neurons. J. Clin. Invest. (2008). doi:10.1172/JCI32751
17. Lee, S. H. et al. Eugenol Inhibits the GABAA Current in Trigeminal Ganglion Neurons. PLoS One 10, e0117316 (2015).
18. Li, H. Y. et al. Eugenol Inhibits K+ Currents in Trigeminal Ganglion Neurons. J. Dent. Res. 86, 898–902 (2007).
19. Khalilzadeh, E., Hazrati, R. & Saiah, G. V. Effects of topical and systemic administration of Eugenia caryophyllata buds essential oil on corneal anesthesia and analgesia. Res. Pharm. Sci. 11, 293–302 (2016).
20. Dal Bó, W., Luiz, A. P., Martins, D. F., Mazzardo-Martins, L. & Santos, A. R. S. Eugenol reduces acute pain in mice by modulating the glutamatergic and tumor necrosis factor alpha (TNF-α) pathways. Fundam. Clin. Pharmacol. 27, 517–525 (2013).
21. Lionnet, L., Beaudry, F. & Vachon, P. Intrathecal eugenol administration alleviates neuropathic pain in male Sprague-Dawley rats. Phyther. Res. 24, 1645–1653 (2010).
22. Pradier, B. et al. The cannabinoid CB2 receptor-selective phytocannabinoid beta-caryophyllene exerts analgesic effects in mouse models of inflammatory and neuropathic pain. Eur. Neuropsychopharmacol. 24, 608–620 (2013).
23. Fiorenzani, P., Lamponi, S., Magnani, A., Ceccarelli, I. & Aloisi, A. M. In Vitro and In Vivo Characterization of the New Analgesic Combination Beta-Caryophyllene and Docosahexaenoic Acid. Evidence-Based Complement. Altern. Med. 2014, 1–12 (2014).
24. Wikimedia Commons. Available at: and (Accessed: 26th April 2019)
25. ICHD-3 The International Classification of Headache Disorders 3rd edition, Trigeminal Neuralgia. 2013 Available at:…. (Accessed: 19th April 2019)
26. ICHD-3 The International Classification of Headache Disorders 3rd edition, Painful Trigeminal Neuropathy. (2013). Available at:…. (Accessed: 3rd March 2019)
27. Rafael, B., Sorin, T. & Eli, E. Painful Traumatic Trigeminal Neuropathy. Oral Maxillofac. Surg. Clin. North Am. 28, 371–380 (2016).

28. Zakrzewska, J. M. Medical management of trigeminal neuropathic pains. Expert Opin. Pharmacother. 11, 1239–1254 (2010).
29. Haviv, Y., Zadik, Y., Sharav, Y. & Benoliel, R. Painful traumatic trigeminal neuropathy: an open study on the pharmacotherapeutic response to stepped treatment. J. oral facial pain headache 28, 52–60 (2014).
30. Belgisch Centrum voor Farmacotherapeutische Informatie (BCFI). Available at: (Accessed: 4th March 2019)
31. Study of NGX-4010 for the Treatment of Postherpetic Neuralgia - Available at: (Accessed: 20th April 2019)
32. Lidocaine and Tetracaine Cream to Treat Postherpetic Neuralgia (PHN) - Full Text View - Available at: (Accessed: 20th April 2019)
33. Nasri-Heir, C., Khan, J. & Heir, G. M. Topical Medications as Treatment of Neuropathic Orofacial Pain. Dent. Clin. North Am. 57, 541–553 (2013).
34. Mallick-Searle, T., Snodgrass, B. & Brant, J. M. Postherpetic neuralgia: epidemiology, pathophysiology, and pain management pharmacology. J. Multidiscip. Healthc. 9, 447–454 (2016).
35. Derry, S., Rice, A. S., Cole, P., Tan, T. & Moore, R. A. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database Syst. Rev. (2017). doi:10.1002/14651858.CD007393.pub4
36. Sommer, C. & Cruccu, G. Topical Treatment of Peripheral Neuropathic Pain: Applying the Evidence. J. Pain Symptom Manage. 53, 614–629 (2017).
37. Derry, S. & Moore, R. A. Topical capsaicin (low concentration) for chronic neuropathic pain in adults. Cochrane Database Syst. Rev. (2012). doi:10.1002/14651858.CD010111
38. Rompelberg, C. et al. Effect of short-term dietary administration of eugenol in humans. Hum. Exp. Toxicol. 15, 129–135 (1996).
39. Fischer, I. U., Von Unruh, G. E. & Dengler, H. J. The metabolism of eugenol in man. Xenobiotica 20, 209–222 (1990).
40. Fischer, I. U. & Dengler, H. J. Sensitive high-performance liquid chromatographic assay for the determination of eugenol in body fluids. J. Chromatogr. B Biomed. Sci. Appl. 525, 369–377 (1990).
41. Ibrahim, I. M., Elsaie, M. L., Almohsen, A. M. & Mohey-Eddin, M. H. Effectiveness of topical clove oil on symptomatic treatment of chronic pruritus. J. Cosmet. Dermatol. 16, 508–511 (2017).
42. Alqareer, A., Alyahya, A. & Andersson, L. The effect of clove and benzocaine versus placebo as topical anesthetics. J. Dent. 34, 747–750 (2006).

43. Nethravathi, V. & Vijaitha, V. Effectiveness of Clove oil massage on Lower Back Pain among Post Natal Mothers at Selected Hospitals, Bangalore. Asian J. Nurs. Educ. Res. 5, 467 (2015).
44. Elwakeel, H. A., Moneim, H. A., Farid, M. & Gohar, A. A. Clove oil cream: a new effective treatment for chronic anal fissure. Color. Dis. 9, 549–552 (2007).
45. Rothenstein, A. S. et al. Eugenol and clove leaf oil: A survey of consumer patch-test sensitization. Food Chem. Toxicol. 21, 727–733 (1983).
46. Prashar, A., Locke, I. C. & Evans, C. S. Cytotoxicity of clove (Syzygium aromaticum) oil and its major components to human skin cells. Cell Prolif. 39, 241–248 (2006).
47. Dyrbye, B A; Dubois, L; Vink, R; Horn, J. A patient with clove oil intoxication. Anaesth. Intensive Care 40, 365–6 (2012).
48. Koopman, J. S. H. A. et al. Incidence of facial pain in the general population. Pain 147, 122–127 (2009).
49. Backonja, M. et al. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. Lancet Neurol. 7, 1106–1112 (2008).
50. A Study With Lidocaine 5% Medicated Plaster in Patients Suffering From Postherpetic Neuralgia -
51. Svedman, C. et al. A pilot study aimed at finding a suitable eugenol concentration for a leave-on product for use in a repeated open application test. Contact Dermatitis 66, 137–139 (2012).
52. Kulkantrakorn, K., Lorsuwansiri, C. & Meesawatsom, P. 0.025% Capsaicin Gel for the Treatment of Painful Diabetic Neuropathy: A Randomized, Double-Blind, Crossover, Placebo-Controlled Trial. Pain Pract. 13, 497–503 (2013).
53. Hassan, H. A. et al. Topical Eugenol Successfully Treats Experimental <b><i>Candida albicans</i></b>-Induced Keratitis. Ophthalmic Res. 60, 69–79 (2018).
54. Heir, G. et al. Use of topical medication in orofacial neuropathic pain: a retrospective study. Oral Surgery, Oral Med. Oral Pathol. Oral Radiol. Endodontology 105, 466–469 (2008).
55. Sayanlar, J., Guleyupoglu, N., Portenoy, R. & Ashina, S. Trigeminal postherpetic neuralgia responsive to treatment with capsaicin 8 % topical patch: a case report. J. Headache Pain 13, 587–589 (2012).
56. Kamatou, G. P., Vermaak, I. & Viljoen, A. M. Eugenol--from the remote Maluku Islands to the international market place: a review of a remarkable and versatile molecule. Molecules 17, 6953–81 (2012).

Universiteit of Hogeschool
Bachelor in de Geneeskunde
Prof. Dr. Bart Morlion
Share this on: